2024-05-16 14:00:49 ET
Summary
- Roche has joined the race to develop an obesity drug with promising weight loss data for its candidate CT-388.
- In a press release issued today, Roche revealed mean weight loss of ~19% at week 24.
- This is comparable with the rates achieved by Lilly's Zepbound and Novo Nordisk's Wegovy - both drugs are expected to be dominant players in a >$100bn obesity market.
- With Lilly's and Novo's share price trading at unprecedented highs, Roche is emerging as an intriguing horse to back in the obesity market.
Investment Overview - Roche Stock Flatlines While Lilly, Novo Stock Explodes - A Simple Explanation
Read the full article on Seeking Alpha
For further details see:
Roche: Targeting Mega-Money Obesity Markets After Sharing Stunning Weight Loss Data